| Bioactivity | BMS-986299 (compound 112) is a first-in-class NLRP3 inflammasome agonist with an EC50 of 1.28 μM. (patent WO2018152396A1). | ||||||||||||
| Name | BMS-986299 | ||||||||||||
| CAS | 2242952-69-6 | ||||||||||||
| Formula | C18H19N7O | ||||||||||||
| Molar Mass | 349.39 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Gary Glick, et al. Substituted imidazo-quinolines as nlrp3 modulators. WO2018152396A1. |
BMS-986299
CAS: 2242952-69-6 F: C18H19N7O W: 349.39
BMS-986299 (compound 112) is a first-in-class NLRP3 inflammasome agonist with an EC50 of 1.28 μM. (patent WO2018152396A
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.